1 / 92

1 6 th CROI, Montreal, 200 9 . Hotel AC Forum, Barcelona – February 20 th 2009

1 6 th CROI, Montreal, 200 9 . Hotel AC Forum, Barcelona – February 20 th 2009. Summary: Opportunistic Infections HCV/HBVCo-Infections &Tumors. José M. Miró Infectious Diseases Unit - ICMiD Hospital Clinic - IDIBAPS University of Barcelona Barcelona (Spain).

dareh
Download Presentation

1 6 th CROI, Montreal, 200 9 . Hotel AC Forum, Barcelona – February 20 th 2009

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. 16th CROI, Montreal, 2009. Hotel AC Forum, Barcelona – February 20th 2009 Summary: Opportunistic Infections HCV/HBVCo-Infections &Tumors • José M. Miró • Infectious Diseases Unit - ICMiD • Hospital Clinic - IDIBAPS • University of Barcelona • Barcelona (Spain) E-mail address: jmmiro@ub.edu

  2. OIs, Hepatitis Coinfections & Tumors • Tuberculosis • Other opportunistic infections • IRIS • HBV & HCV co-infections • Cirrhosis & liver transplantation • Tumors N= 44 N= 19 N= 11 N= 77 N= 5 N= 17 ~173 abstracts in 20 min. ! http://www.retroconference.org/2009

  3. OIs, Hepatitis Coinfections & Tumors • Tuberculosis • Other opportunistic infections • IRIS • HBV & HCV co-infections • Cirrhosis & liver transplantation • Tumors

  4. Abs. # 36bLB

  5. Abs. # 36bLB

  6. Abs. # 36bLB

  7. Abs. # 36bLB

  8. Abs. # 36bLB

  9. Abs. # 36bLB

  10. Abs. # 36bLB

  11. Abs. # 36bLB

  12. Abs. # 36bLB

  13. Abs. # 35

  14. Abs. # 35

  15. Abs. # 35

  16. Abs. # 35

  17. Abs. # 35

  18. Abs. # 36a

  19. Abs. # 36a

  20. Abs. # 36a

  21. Abs. # 36a

  22. Abs. # 36a

  23. Abs. # 36a

  24. Abs. # 36a

  25. Abs. # 36cLB

  26. Abs. # 36cLB

  27. Abs. # 36cLB

  28. Abs. # 36cLB

  29. Abs. # 36cLB

  30. OIs, Hepatitis Coinfections & Tumors • Tuberculosis • Other opportunistic infections • IRIS • HBV & HCV co-infections • Cirrhosis & liver transplantation • Tumors

  31. Clinical Relevance of CMV viremiaBoffi E, et al. CROI 2009, Montreal; Abstract 795. 1,170 Patients: CMV specific IgG positive, CD4≤ 100; Swiss HIV Cohort.

  32. Abs. # 32

  33. Abs. # 32

  34. Abs. # 32

  35. Abs. # 32

  36. OIs, Hepatitis Coinfections & Tumors • Tuberculosis • Other opportunistic infections • IRIS • HBV & HCV co-infections • Cirrhosis & liver transplantation • Tumors

  37. Immediate vs. Deferred cART in the Setting of Acute AIDS-Related OIs (ACTG A5164)Zolopa AR, et al. CROI 2008, Boston; Abstract 142. Study schema OI/BI Treatment Starts Immediate Arm Start ART 48 wks Deferred Arm Start ART 48 wks Recommended Start window -14 0 2 28 42 84 224 Study day Higher mortality deferred arm ! Enrollment

  38. Immediate vs. Deferred cART in the Setting of Acute AIDS-Related OIs (ACTG A5164)Zolopa AR, et al. CROI 2008, Boston; Abstract 142.

  39. Risk Factors for IRIS during a RCT of Early vs. Deferred cART in AIDS-Related OIs (ACTG A5164)Grant P, et al. CROI 2009, Montreal; Abstract 775.

  40. Abs. # 34

  41. Abs. # 34

  42. Abs. # 34

  43. Abs. # 34

  44. Abs. # 34

  45. Abs. # 34

  46. Abs. # 34

  47. OIs, Hepatitis Coinfections & Tumors • Tuberculosis • Other opportunistic infections • IRIS • HBV & HCV co-infections • Cirrhosis & Liver transplantation • Tumors

  48. Efficacy of rGM-CSF as an Adjuvant for HBV Vaccination in Adults Infected with HIV-1Parker S. CROI 2009, Montreal; Abstract 808.

  49. Does Telbivudine (Tyzeka) Have Activity Against HIV?CROI 2009, Montreal; Abstracts 813a & 813b. Yes, Case Report Suggests Anti-HIV Activity Lab Studies Say No ! Entecavir Telbivudine Avila C et al. Abs. 813b Low E et al. Abs. 813a

  50. Abs. # 101

More Related